Company Overview of YM BioSciences USA Inc.
YM BioSciences USA Inc. produces, acquires, and commercializes products for the treatment of cancer, cancer-related disorders, and infectious diseases. Its portfolio includes therapeutic oncology products, including THYMITAQ, a nolatrexed dihydrochloride for the treatment of patients with inoperable primary liver cancer; and ORATAQ, an oral form of nolatrexed. The company was formerly known as EXIMIAS Pharmaceutical Corporation and changed its name to YM BioSciences USA Inc. in May, 2006. The company was founded in 1998 and is based in Winchester, Massachusetts. As of May 9, 2006, YM BioSciences USA Inc. operates as a subsidiary of YM BioSciences Inc.
10 Priscilla Lane
Winchester, MA 01890
Founded in 1998
Key Executives for YM BioSciences USA Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Sponsored Financial Commentaries
To contact YM BioSciences USA Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.